文献速递肥胖与代谢综合征糖尿病

口服orforglipron治疗日本肥胖症的3期随机对照试验

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-10-30

ATTAIN-J是一项在日本进行的双盲、随机、安慰剂对照3期试验,纳入238例肥胖症成人。不良事件以轻中度胃肠道症状为主。

要点

  • orforglipron 6/12/36 mg治疗72周体重降幅均显著优于安慰剂。
  • 不良事件以轻中度胃肠道症状为主,恶心呕吐可致停药。

核心结论

  • 在日本肥胖症成人中,每日一次口服orforglipron较安慰剂显著降低体重,安全性与其他GLP-1受体激动剂一致。

研究设计与样本

  • ATTAIN-J为双盲、随机、安慰剂对照、平行组3期试验,在日本16个医学研究中心和医院开展。
  • 纳入238例成人,按1:1:1:1随机分配至orforglipron 6 mg、12 mg、36 mg或安慰剂组。

主要发现

  • 导致停药的治疗中出现的不良事件:恶心在6 mg组1/61(2%)、12 mg组1/57(2%)、36 mg组5/60(8%),安慰剂组无;呕吐在6 mg组无、12 mg组2/57(4%)、36 mg组1/60(2%),安慰剂组无。

关键数值与推荐

  • 主要终点为第72周体重平均百分比变化和体重减轻至少5%的参与者百分比。
  • 疗效主要按治疗方案估计目标在所有随机分配参与者中评估,安全性在至少接受一剂研究治疗的参与者中评估。

临床怎么用

  • 对于日本肥胖症成人,每日一次口服orforglipron可作为减重治疗选择,需关注胃肠道不良反应及停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across phase 3 trials globally. We aimed to assess the efficacy and safety of orforglipron versus placebo for treating obesity disease in Japanese adults. METHODS: ATTAIN-J was a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial conducted across 16 medical research centres and hospitals in Japan and included adults aged 18 years or older with a BMI between 27 kg/m2 and less than 35 kg/m2 and two or more obesity-related health disorders, or a BMI of 35 kg/m2 or higher and one or more obesity-related health disorder, with one or more of the obesity-related health disorders being hypertension, dyslipidaemia, or type 2 diabetes (targeted at about 25% of participants), consistent with Japanese indications for tirzepatide and semaglutide for obesity disease; and at least one unsuccessful dietary attempt to lose weight. Participants were randomly assigned (1:1:1:1) via a computer-generated sequence to once-daily oral orforglipron (6 mg, 12 mg, or 36 mg) or placebo. Co-primary endpoints were mean percentage change in bodyweight and percentage of participants with at least 5% bodyweight reduction from baseline to week 72. Efficacy endpoints were primarily evaluated by the treatment regimen estimand in all randomly assigned participants. Safety was assessed in participants who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT05931380 (completed). FINDINGS: Between July 31, 2023, and June 19, 2025, 291 participants were screened, of whom 238 (144 [61%] males and 94 [39%] females; mean age 54·1 years [SD 11·2]) were randomly assigned to receive orforglipron 6 mg (n=61), 12 mg (n=57), or 36 mg (n=60), or placebo (n=60); 214 (90%) participants completed the study. At week 72, mean percentage change in bodyweight was -5·9% (95% CI -7·6 to -4·2) with orforglipron 6 mg, -8·7% (-10·9 to -6·5) with 12 mg, and -7·9% (-10·0 to -5·8) with 36 mg, compared with -0·6% (-2·1 to 0·8) with placebo (all p<0·0001 vs placebo). At week 72, a bodyweight reduction of at least 5% was seen in 15·2% (SE 4·8; nine of 60) of participants in the placebo group compared with 45·6% (6·1; 28 of 61; p=0·0001) of participants in the orforglipron 6 mg group, 60·8% (6·4; 35 of 57; p<0·0001) of participants in the orforglipron 12 mg group, and 58·8% (6·5; 35 of 60; p<0·0001) of participants in the orforglipron 36 mg group. Adverse events with orforglipron were mostly mild-to-moderate gastrointestinal symptoms. Across all orforglipron groups, treatment-emergent adverse events that most frequently led to study treatment discontinuation were nausea (one [2%] of 61 in the 6 mg group, one [2%] of 57 in the 12 mg group, and five [8%] of 60 in the 36 mg group vs none with placebo) and vomiting (none in the 6 mg group, two [4%] in the 12 mg group, and one [2%] in the 36 mg group vs none in the placebo group). INTERPRETATION: In Japanese adults with obesity disease, once-daily orforglipron resulted in statistically superior reductions in bodyweight versus placebo, with a safety profile consistent with that of other GLP-1 receptor agonists. FUNDING: Eli Lilly and Company. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Yokote K, Yamauchi T, Shingaki T, et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42962687. doi:10.1016/S2213-8587(26)00232-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。